Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease

July 2017

Xadago (ZAH-dah-goh) will be a new add-on for Parkinson's disease.

Think of Xadago (safinamide) as similar to selegiline (Eldepryl, etc) or rasagiline (Azilect, etc).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote